Comment: compulsory licensing of patented pharmaceutical inventions: evaluating the options
- PMID: 19493070
- PMCID: PMC2893582
- DOI: 10.1111/j.1748-720X.2009.00369.x
Comment: compulsory licensing of patented pharmaceutical inventions: evaluating the options
Abstract
In this Comment, the author traces the relevant legislative history pertaining to compulsory licensing of patented pharmaceuticals from the TRIPS Agreement of 1994 to the 2003 waiver to, and later proposed amendment of, article 31, which enables poor countries to obtain needed medicines from other countries that possess manufacturing capacity. The Comment then evaluates recent, controversial uses of the relevant legislative machinery as viewed from different critical perspectives. The Comment shows how developing countries seeking access to essential medicines can collaborate in ways that would avoid undermining incentives to innovation and other social costs attributed to compulsory licensing. It ends by defending the legality of recent measures taken to promote public health in developing countries, and by reminding developed countries that unilateral retaliation against such measures is demonstratably illegal under WTO foundational law and jurisprudence.
Similar articles
-
Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.J Law Med Ethics. 2009 Summer;37(2):209-21. doi: 10.1111/j.1748-720X.2009.00366.x. J Law Med Ethics. 2009. PMID: 19493067
-
Compulsory licensing in Canada and Thailand: comparing regimes to ensure legitimate use of the WTO rules.J Law Med Ethics. 2009 Summer;37(2):222-39. doi: 10.1111/j.1748-720X.2009.00367.x. J Law Med Ethics. 2009. PMID: 19493068
-
An economic justification for open access to essential medicine patents in developing countries.J Law Med Ethics. 2009 Summer;37(2):184-208. doi: 10.1111/j.1748-720X.2009.00365.x. J Law Med Ethics. 2009. PMID: 19493066
-
Differential pricing for pharmaceuticals: reconciling access, R&D and patents.Int J Health Care Finance Econ. 2003 Sep;3(3):183-205. doi: 10.1023/a:1025384819575. Int J Health Care Finance Econ. 2003. PMID: 14625999 Review.
-
The ethics and economics of pharmaceutical pricing.Annu Rev Pharmacol Toxicol. 2015;55:191-206. doi: 10.1146/annurev-pharmtox-010814-124649. Epub 2014 Aug 13. Annu Rev Pharmacol Toxicol. 2015. PMID: 25149920 Review.
Cited by
-
The use of generic medications for hepatitis C.Liver Int. 2016 Jul;36(7):929-32. doi: 10.1111/liv.13157. Liver Int. 2016. PMID: 27306303 Free PMC article.
-
The changing life science patent landscape.Nat Biotechnol. 2016 Mar;34(3):292-4. doi: 10.1038/nbt.3504. Nat Biotechnol. 2016. PMID: 26963552 No abstract available.
-
Do March-In Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative Study.Milbank Q. 2015 Dec;93(4):761-87. doi: 10.1111/1468-0009.12164. Milbank Q. 2015. PMID: 26626985 Free PMC article.
-
Legal agreements and the governance of research commons: lessons from materials sharing in mouse genomics.OMICS. 2014 Apr;18(4):254-73. doi: 10.1089/omi.2013.0158. Epub 2014 Feb 19. OMICS. 2014. PMID: 24552652 Free PMC article.
-
Using TRIPS flexibilities to facilitate access to medicines.Bull World Health Organ. 2013 Jul 1;91(7):533-9. doi: 10.2471/BLT.12.115865. Epub 2013 Apr 18. Bull World Health Organ. 2013. PMID: 23825881 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
